Cognitive changes mediated by adenosine receptor blockade in a resveratrol-treated atherosclerosis-prone lupus mouse model

10.1016/j.jtcme.2022.01.006

Lora J. Kasselman；Heather A. Renna；Iryna Voloshyna；Aaron Pinkhasov；Irving H. Gomolin；Isaac Teboul；Joshua De Leon；Steven E. Carsons；Allison B. Reiss

Systemic lupus erythematosus ； Cognition ； Neurolupus ； Nutraceutical ； Cardiovascular

Journal of Traditional and Complementary Medicine

12卷5期（2022 / 09 / 01）

447 - 454

英文

Background and aim: Resveratrol is a bioactive molecule used in dietary supplements and herbal medicines and consumed worldwide. Prior work showed that resveratrol's anti-atherogenic properties are mediated in part through the adenosine A2A receptor. The present study explores the potential contribution of adenosine A2A receptor activation to neuroprotective action of resveratrol on cognitive deficits in a model of atherosclerosis-prone systemic lupus erythematosus. Experimental procedure: Using behavioral analysis (open field, static rod, novel object recognition) and QRT-PCR, this study measured working memory, anxiety, motor coordination, and expression of mRNA in the brain. Results and conclusion: Data indicate that resveratrol increases working memory, on average but not statistically, and shows a trend towards improved motor coordination (p = 0.07) in atherosclerosis-prone lupus mice. Additionally, resveratrol tends to increase mRNA levels of SIRT1, decrease vascular endothelial growth factor and CX3CL1 mRNA in the hippocampus. Istradefylline, an adenosine A2A receptor antagonist, antagonizes the effects of resveratrol on working memory (p = 0.04) and the expression of SIRT1 (p = 0.03), vascular endothelial growth factor (p = 0.04), and CX3CL1 (p = 0.03) in the hippocampus. This study demonstrates that resveratrol could potentially be a therapeutic candidate in the modulation of cognitive dysfunction in neuropsychiatric lupus, especially motor incoordination. Further human studies, as well as optimization of resveratrol administration, could confirm whether resveratrol may be an additional resource available to reduce the burden of cognitive impairment associated with lupus. Additionally, further studies need to address the role of A2A blockade in cognitive function among the autoimmune population. Section: 3. Dietary therapy/nutrients supplements. Taxonomy (classification by EVISE): autoimmunity, inflammation, neurology.

1. Afeltra, A,Garzia, P,Mitterhofer, AP(2003).Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies.Neurology,61(1),108-110.
2. Andrade, S,Ramalho, MJ,Pereira, MC,Loureiro, JA(2018).Resveratrol brain delivery for neurological disorders prevention and treatment.Front Pharmacol,9,1261.
3. Appenzeller, S,Costallat, LT,Cendes, F(2006).Neurolupus.Arch Neurol,63(3),458-460.
4. Bastianetto, S,Ménard, C,Quirion, R(2015).Neuroprotective action of resveratrol.Biochim Biophys Acta,1852(6),1195-1201.
5. Baur, JA,Sinclair, DA(2006).Therapeutic potential of resveratrol: the in vivo evidence.Nat Rev Drug Discov.,5(6),493-506.
6. Bendorius, M,Po, C,Muller, S,Jeltsch-David, H(2018).From systemic inflammation to neuroinflammation: the case of neurolupus.Int J Mol Sci.,19(11)
7. Bobermin, LD,Roppa, RHA,Quincozes-Santos, A(2019).Adenosine receptors as a new target for resveratrol-mediated glioprotection.Biochim Biophys Acta (BBA) -Mol Basis Dis,1865(3),634-647.
8. Böckle, BC,Jara, D,Aichhorn, K(2014).Cerebral large vessel vasculitis in systemic lupus erythematosus.Lupus,23(13),1417-1421.
9. Brey, RL,Amato, AA,Kagan-Hallet, K,Rhine, CB,Stallworth, CL(1997).Anti-intercellular adhesion molecule-1 (ICAM-1) antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice.Lupus,6(8),645-651.
10. Brey, RL,Holliday, SL,Saklad, AR,Navarrete, MG,Hermosillo-Romo, D(2002).Neuropsychiatric syndromes in lupus: prevalence using standardized definitions.Neurology,58,1214-1220.
11. Chen, PZ,He, WJ,Zhu, ZR(2018).Adenosine A2A receptor involves in neuroinflammation-mediated cognitive decline through activating microglia under acute hypobaric hypoxia.Behav Brain Res,347,99-107.
12. Cope, EC,LaMarca, EA,Monari, PK(2018).Microglia play an active role in obesity-associated cognitive decline.J Neurosci,38(41),8889-8904.
13. Croker, BP,Gilkeson, G,Morel, L(2003).Genetic interactions between susceptibility loci reveal epistatic pathogenic networks in murine lupus.Gene Immun,4,575-585.
14. Cunha, RA(2008).Different cellular sources and different roles of adenosine: a1 receptor-mediated inhibition through astrocytic-driven volume transmission and synapse-restricted A2A receptor-mediated facilitation of plasticity.Neurochem Int,52,65-72.
15. Du, SQ,Wang, XR,Xiao, LY(2017).Molecular mechanisms of vascular dementia: what can Be learned from animal models of chronic cerebral hypoperfusion?.Mol Neurobiol,54(5),3670-3682.
16. Duarte-García, A,Romero-Díaz, J,Juárez, S(2018).Disease activity, autoantibodies, and inflammatory molecules in serum and cerebrospinal fluid of patients with Systemic Lupus Erythematosus and Cognitive Dysfunction.PLoS One,13(5),e0196487.
17. Feng, X,Li, H,Rumbin, AA(2007).ApoE-/-Fas-/-C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia.J Lipid Res,48,794-805.
18. Ferrante, A,Pezzola, A,Matteucci, A(2018).The adenosine A2A receptor agonist T1-11 ameliorates neurovisceral symptoms and extends the lifespan of a mouse model of Niemann-Pick type C disease.Neurobiol Dis,110,1-11.
19. Francioso, A,Mastromarino, P,Masci, A,Erme, M,Mosca, L(2014).Chemistry, stability and bioavailability of resveratrol.Med Chem,10,237-245.
20. Gorelick, PB,Scuteri, A,Black, SE(2011).American heart association stroke council, council on epidemiology and prevention, council on cardiovascular nursing, council on cardiovascular radiology and intervention, and council on cardiovascular surgery and anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.Stroke,42(9),2672-2713.
21. Hopperton, KE,Trépanier, MO,Giuliano, V,Bazinet, RP(2016).Brain omega-3 poly-unsaturated fatty acids modulate microglia cell number and morphology in response to intracerebroventricular amyloid-β 1-40 in mice.J Neuroinflammation,13(1),257.
22. Hung, LM,Chen, JK,Huang, SS,Lee, RS,Su, MJ(2000).Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes.Cardiovasc Res,47(3),549-555.
23. Jeltsch-David, H,Muller, S(2014).Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers.Nat Rev Neurol,10(10),579-596.
24. Joseph, FG,Scolding, NJ(2010).Neurolu.Pract Neurol,10(1),4-15.
25. Kalinowska-Łyszczarz, A,Pawlak, MA,Pietrzak, A(2018).Subcortical gray matter atrophy is associated with cognitive deficit in multiple sclerosis but not in systemic lupus erythematosus patients.Lupus,27(4),610-620.
26. Karaaslan, Z,Ekizoğlu, E,Tektürk, P(2017).Investigation of neuronal auto-antibodies in systemic lupus erythematosus patients with epilepsy.Epilepsy Res,129,132-137.
27. Kuban, KC,Joseph, RM,O'Shea, TM(2017).Extremely low gestational age newborn (ELGAN) study investigators. Circulating inflammatory-associated proteins in the first month of life and cognitive impairment at age 10 Years in children born extremely preterm.J Pediatr,180,116-123.e1.
28. Li, Z,Chen, X,Wang, T(2018).The corticostriatal adenosine A2A receptor controls maintenance and retrieval of spatial working memory.Biol Psychiatr,83(6),530-541.
29. Mackay, M.(2015).Lupus brain fog: a biologic perspective on cognitive impairment, depression, and fatigue in systemic lupus erythematosus.Immunol Res,63(1-3),26-37.
30. Manzi, S,Meilahn, EN,Rairie, JE(1997).Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study.Am J Epidemiol,145,408-415.
31. McGlasson, S,Wiseman, S,Wardlaw, J,Dhaun, N,Hunt, DPJ(2018).Neurological disease in lupus: toward a personalized medicine approach.Front Immunol,9,1146.
32. McLean, BN,Miller, D,Thompson, EJ(1995).Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet's disease involving the nervous system.J Neurol Neurosurg Psychiatry,58(5),548-554.
33. Muscal, E,Brey, RL(2010).Neurologic manifestations of systemic lupus erythematosus in children and adults.Neurol Clin,28(1),61-73.
34. Oliveira, WH,Nunes, AK,França, ME(2016).Effects of metformin on inflammation and short-term memory in streptozotocin-induced diabetic mice.Brain Res,1644,149-160.
35. Østergaard, L,Engedal, TS,Moreton, F(2016).Cerebral small vessel disease: capillary pathways to stroke and cognitive decline.J Cerebr Blood Flow Metabol,36(2),302-325.
36. Pamfil, C,Fanouriakis, A,Damian, L(2015).EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres.Rheumatology,54(7),1270-1278.
37. Piedrahita, JA,Zhang, SH,Hagaman, JR,Oliver, PM,Maeda, N(1992).Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells.Proc Natl Acad Sci U S A,89(10),4471-4475.
38. Pittet, F,Van, Caenegem, N,Hicks-Nelson, AR(2019).Maternal social environment affects offspring cognition through behavioural and immune pathways in rats.J Neuroendocrinol,e12711.
39. Porrini, V,Lanzillotta, A,Branca, C(2015).CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid.Neuroscience,302,112-120.
40. Reiss, AB,Cronstein, BN(2012).Regulation of foam cells by adenosine.Arterioscler Thromb Vasc Biol,32(4),879-886.
41. Reiss, AB,Rahman, MM,Chan, ESL,Montesinos, MC,Awadallah, NW,Cronstein, BN(2004).Adenosine A2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages.J Leukoc Biol,76(3),727-734.
42. Shastri, R,Shah, G,Wang, P(2016).MR diffusion tractography to identify and characterize microstructural white matter tract changes in systemic lupus erythematosus patients.Acad Radiol,23(11),1431-1440.
43. Singh, UP,Singh, NP,Singh, B(2010).Resveratrol (trans-3,5,4'-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis.J Pharmacol Exp Therapeut,332(3),829-839.
44. Summerlin, N,Soo, E,Thakur, S,Qu, Z,Jambhrunkar, S,Popat, A(2015).Resveratrol nanoformulations: challenges and opportunities.Int J Pharm,479,282-290.
45. Suzuki, K,Miyamoto, M,Miyamoto, T(2017).Istradefylline improves daytime sleepiness in patients with Parkinson's disease: an open-label, 3-month study.J Neurol Sci,380,230-233.
46. Taha, S,Gamal, SM,Nabil, M(2017).Vascular endothelial growth factor G1612A (rs10434) gene polymorphism and neuropsychiatric manifestations in systemic lupus erythematosus patients.Rev Bras Reumatol Engl Ed,57(2),149-153.
47. Tan, Z,Zhou, Y,Li, X(2018).Brain magnetic resonance imaging, cerebrospinal fluid, and autoantibody profile in 118 patients with neuropsychiatric lupus.Clin Rheumatol,37(1),227-233.
48. Todd, MA(2017).Inflammation and cognition in older adults: evidence from taiwan.Biodemogr Soc Biol,63(4),309-323.
49. Vasamsetti, SB,Karnewar, S,Gopoju, R(2016).Resveratrol attenuates monocyte-tomacrophage differentiation and associated inflammation via modulation of intracellular GSH homeostasis: relevance in atherosclerosis.Free Radic Biol Med,96,392-405.
50. Voloshyna, I,Hai, O,Littlefield, MJ,Carsons, SE,Reiss, AB(2013).Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPAR-g and adenosine.Eur J Pharmacol,698(1-3),299-309.
51. Voloshyna, I,Teboul, I,Littlefield, MJ(2016).Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux.Exp Biol Med,241(14),1611-1619.
52. Wightman, EL,Haskell-Ramsay, CF,Reay, JL(2015).The effects of chronic trans-resveratrol supplementation on aspects of cognitive function, mood, sleep, health and cerebral blood flow in healthy, young humans.Br J Nutr,114(9),1427-1437.
53. Xiao, Q,Yu, W,Tian, Q(2017).Chitinase1 contributed to a potential protection via microglia polarization and Aß oligomer reduction in D-galactose and aluminum-induced rat model with cognitive impairments.Neuroscience,355,61-70.
54. Zameer, A,Hoffman, SA(2003).Increased ICAM-1 and VCAM-1 expression in the brains of autoimmune mice.J Neuroimmunol,142(1-2),67-74.
55. Zhang, S,Gao, L,Liu, X,Lu, T,Xie, C,Jia, J(2017).Resveratrol attenuates microglial activation via SIRT1-SOCS1 pathway.Evid Based Compl Alternat Med,2017,8791832.